Acacia Research Corporation (Nasdaq:ACTG) announced today that a
subsidiary has acquired patents for x-ray powder diffraction technology.
“Acacia continues to increase the number of patent portfolios we control
in the medical device and diagnostics sectors,” commented Paul Ryan, CEO
and President. “Acacia is rapidly expanding its presence as a leader in
patent licensing for both the technology and medical technology sectors.”
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation’s subsidiaries partner with inventors and
patent owners, license the patents to corporate users, and share the
revenue. Acacia Research Corporation’s subsidiaries control over 200
patent portfolios, covering technologies used in a wide variety of
industries.
Information about Acacia Research Corporation and its subsidiaries is
available at www.acaciaresearchgroup.com
and www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon
our current expectations and speak only as of the date hereof. Our
ability to become the licensing partner for companies, and our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the recent economic slowdown affecting
technology companies, the ability to successfully develop
licensing programs and attract new business, rapid technological change
in relevant markets, changes in demand for current and future
intellectual property rights, legislative, regulatory and competitive
developments addressing licensing and enforcement of patents and/or
intellectual property in general, and general economic conditions. Our
Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on
Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC
filings discuss some of the important risk factors that may affect our
business, results of operations and financial condition. We
undertake no obligation to revise or update publicly any forward-looking
statements for any reason.
